Hematopoietic Stem Cell Transplantation in the Eastern Mediterranean Region (EMRO) 2008-2009: Report on behalf of the Eastern Mediterranean Bone Marrow Transplantation (EMBMT) Group

Said Yousef Ahmed Mohamed, Ibtihal Fadhil, Rose Marie Hamladji, Amir Ali Hamidieh, Omar Fahmy, Saloua Ladeb, Kamran Alimoghaddam, Alaa Elhaddad, Redhouane Ahmed Nacer, Fahad Alsharif, Walid Rasheed, Mohammad Jahani, Seyed Asadollah Mousavi, Amal Alseraihy, Fawzi Abdel-Rahman, Abdullah Al Jefri, Ayad Ahmed Hussein, Abdulaziz Alabdulaaly, Ahmad Ibrahim, Mohamed Amine BekadjaMiguel Abboud, Parvez Ahmed, David Dennison, Mohammad Bakr, Said Benchekroun, Fazal Hussain, Tarek Ben Othman, Mahmoud Aljurf, Ardeshir Ghavamzadeh

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: The Eastern Mediterranean Bone Marrow Transplantation (EMBMT) Group has accumulated over 25 years of data and experience in hematopoietic stem cell transplantation (HSCT), most particularly in hem-moglobinopathies, severe aplastic anemia (SAA), and inherited metabolic and immune disorders, in addition to hematologic malignancies peculiar to the region and where recent updates in trends in activities are warranted. Objectives: To study trends in HSCT activities in the World Health Organization-Eastern Mediterranean (EM) region surveyed by EMBMT between 2008 and 2009. STUDY DESIGN: Retrospective analysis of the survey data, mainly of the cumulative number of transplants, types of transplants (autologous vs. allogeneic), types of conditioning as myeloablative (MAC) vs. reduced intensity conditioning (RIC) and trends in leukemias, hemog-globinopathies, SAA, inherited bone marrow failure syndromes amongst others. Results And Discussion: Fourteen teams from ten Eastern Mediterranean Region Organization (EMRO) countries reported their data (100% return rate) to the EMBMT for the years 2008-2009 with a total of 2608 first HSCT (1286 in 2008; 1322 in 2009). Allogeneic HSCT represented the majority (63%) in both years. The main indications for allogeneic HSCT were acute leukemias (732; 44%), bone marrow failure syndromes (331, 20%), hemoglobinopathies (255; 15%) and immune deficiencies (90; 5%). There was a progressive increase in the proportions of chronic myeloid leukemia (CML) cases transplanted beyond the first chronic phase (3; 7% of all CML cases in 2008 vs 13; 29% in 2009). The main indications for autologous transplants were plasma cell disorders (345; 36%) Hodgkin disease (256; 27%), non-Hodgkin lymphoma (207; 22%) and solid tumors (83; 9%). RIC continued to show a progressive increase over the years (7% in 2007, 11% in 2008 and 13% in 2009), yet remained relatively low compared to contemporary practices in Europe published by EBMT. The vast majori-ity (95%) of allo-HSCT sources were from sibling donors with a continued dominance of peripheral blood (PB) (1076; 63%), while cord blood transplant (CBT) increased to 83 (5% of allo-HSCT), matched unrelated donor (MUD) remained underutilized (1; 0%) and there were no haploidentical transplants reported. Large centers with >50 HSCT/year showed a plateau of the total number of allo-HSCT over the last 5 years that may be related to capacity issues and needs further study. Conclusions And Recommendations: There is an overall increased rate of HSCT in the EMRO region with a significant increase in utilization of CBT and allogeneic PB-HSCT as a valuable source. However, further research on outcome data and development of regional donor banks (CB and MUD) may help facilitate future planning to satisfy the regional needs and increase collaboration within the group and globally.

Original languageEnglish
Pages (from-to)81-93
Number of pages13
JournalHematology/ Oncology and Stem Cell Therapy
Volume4
Issue number2
DOIs
Publication statusPublished - 2011

Fingerprint

Mediterranean Region
Hematopoietic Stem Cell Transplantation
Bone Marrow Transplantation
Transplants
Unrelated Donors
Aplastic Anemia
Autografts
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Fetal Blood
Leukemia
Tissue Donors
Peripheral Blood Stem Cell Transplantation
Hemoglobinopathies
Immune System Diseases
Hematologic Neoplasms
Plasma Cells
Hodgkin Disease
Non-Hodgkin's Lymphoma
Siblings

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Hematopoietic Stem Cell Transplantation in the Eastern Mediterranean Region (EMRO) 2008-2009 : Report on behalf of the Eastern Mediterranean Bone Marrow Transplantation (EMBMT) Group. / Mohamed, Said Yousef Ahmed; Fadhil, Ibtihal; Hamladji, Rose Marie; Hamidieh, Amir Ali; Fahmy, Omar; Ladeb, Saloua; Alimoghaddam, Kamran; Elhaddad, Alaa; Nacer, Redhouane Ahmed; Alsharif, Fahad; Rasheed, Walid; Jahani, Mohammad; Mousavi, Seyed Asadollah; Alseraihy, Amal; Abdel-Rahman, Fawzi; Al Jefri, Abdullah; Hussein, Ayad Ahmed; Alabdulaaly, Abdulaziz; Ibrahim, Ahmad; Bekadja, Mohamed Amine; Abboud, Miguel; Ahmed, Parvez; Dennison, David; Bakr, Mohammad; Benchekroun, Said; Hussain, Fazal; Othman, Tarek Ben; Aljurf, Mahmoud; Ghavamzadeh, Ardeshir.

In: Hematology/ Oncology and Stem Cell Therapy, Vol. 4, No. 2, 2011, p. 81-93.

Research output: Contribution to journalArticle

Mohamed, SYA, Fadhil, I, Hamladji, RM, Hamidieh, AA, Fahmy, O, Ladeb, S, Alimoghaddam, K, Elhaddad, A, Nacer, RA, Alsharif, F, Rasheed, W, Jahani, M, Mousavi, SA, Alseraihy, A, Abdel-Rahman, F, Al Jefri, A, Hussein, AA, Alabdulaaly, A, Ibrahim, A, Bekadja, MA, Abboud, M, Ahmed, P, Dennison, D, Bakr, M, Benchekroun, S, Hussain, F, Othman, TB, Aljurf, M & Ghavamzadeh, A 2011, 'Hematopoietic Stem Cell Transplantation in the Eastern Mediterranean Region (EMRO) 2008-2009: Report on behalf of the Eastern Mediterranean Bone Marrow Transplantation (EMBMT) Group', Hematology/ Oncology and Stem Cell Therapy, vol. 4, no. 2, pp. 81-93. https://doi.org/10.5144/1658-3876.2011.81
Mohamed, Said Yousef Ahmed ; Fadhil, Ibtihal ; Hamladji, Rose Marie ; Hamidieh, Amir Ali ; Fahmy, Omar ; Ladeb, Saloua ; Alimoghaddam, Kamran ; Elhaddad, Alaa ; Nacer, Redhouane Ahmed ; Alsharif, Fahad ; Rasheed, Walid ; Jahani, Mohammad ; Mousavi, Seyed Asadollah ; Alseraihy, Amal ; Abdel-Rahman, Fawzi ; Al Jefri, Abdullah ; Hussein, Ayad Ahmed ; Alabdulaaly, Abdulaziz ; Ibrahim, Ahmad ; Bekadja, Mohamed Amine ; Abboud, Miguel ; Ahmed, Parvez ; Dennison, David ; Bakr, Mohammad ; Benchekroun, Said ; Hussain, Fazal ; Othman, Tarek Ben ; Aljurf, Mahmoud ; Ghavamzadeh, Ardeshir. / Hematopoietic Stem Cell Transplantation in the Eastern Mediterranean Region (EMRO) 2008-2009 : Report on behalf of the Eastern Mediterranean Bone Marrow Transplantation (EMBMT) Group. In: Hematology/ Oncology and Stem Cell Therapy. 2011 ; Vol. 4, No. 2. pp. 81-93.
@article{cb0231d6fda7457f940ad21256266e51,
title = "Hematopoietic Stem Cell Transplantation in the Eastern Mediterranean Region (EMRO) 2008-2009: Report on behalf of the Eastern Mediterranean Bone Marrow Transplantation (EMBMT) Group",
abstract = "Background: The Eastern Mediterranean Bone Marrow Transplantation (EMBMT) Group has accumulated over 25 years of data and experience in hematopoietic stem cell transplantation (HSCT), most particularly in hem-moglobinopathies, severe aplastic anemia (SAA), and inherited metabolic and immune disorders, in addition to hematologic malignancies peculiar to the region and where recent updates in trends in activities are warranted. Objectives: To study trends in HSCT activities in the World Health Organization-Eastern Mediterranean (EM) region surveyed by EMBMT between 2008 and 2009. STUDY DESIGN: Retrospective analysis of the survey data, mainly of the cumulative number of transplants, types of transplants (autologous vs. allogeneic), types of conditioning as myeloablative (MAC) vs. reduced intensity conditioning (RIC) and trends in leukemias, hemog-globinopathies, SAA, inherited bone marrow failure syndromes amongst others. Results And Discussion: Fourteen teams from ten Eastern Mediterranean Region Organization (EMRO) countries reported their data (100{\%} return rate) to the EMBMT for the years 2008-2009 with a total of 2608 first HSCT (1286 in 2008; 1322 in 2009). Allogeneic HSCT represented the majority (63{\%}) in both years. The main indications for allogeneic HSCT were acute leukemias (732; 44{\%}), bone marrow failure syndromes (331, 20{\%}), hemoglobinopathies (255; 15{\%}) and immune deficiencies (90; 5{\%}). There was a progressive increase in the proportions of chronic myeloid leukemia (CML) cases transplanted beyond the first chronic phase (3; 7{\%} of all CML cases in 2008 vs 13; 29{\%} in 2009). The main indications for autologous transplants were plasma cell disorders (345; 36{\%}) Hodgkin disease (256; 27{\%}), non-Hodgkin lymphoma (207; 22{\%}) and solid tumors (83; 9{\%}). RIC continued to show a progressive increase over the years (7{\%} in 2007, 11{\%} in 2008 and 13{\%} in 2009), yet remained relatively low compared to contemporary practices in Europe published by EBMT. The vast majori-ity (95{\%}) of allo-HSCT sources were from sibling donors with a continued dominance of peripheral blood (PB) (1076; 63{\%}), while cord blood transplant (CBT) increased to 83 (5{\%} of allo-HSCT), matched unrelated donor (MUD) remained underutilized (1; 0{\%}) and there were no haploidentical transplants reported. Large centers with >50 HSCT/year showed a plateau of the total number of allo-HSCT over the last 5 years that may be related to capacity issues and needs further study. Conclusions And Recommendations: There is an overall increased rate of HSCT in the EMRO region with a significant increase in utilization of CBT and allogeneic PB-HSCT as a valuable source. However, further research on outcome data and development of regional donor banks (CB and MUD) may help facilitate future planning to satisfy the regional needs and increase collaboration within the group and globally.",
author = "Mohamed, {Said Yousef Ahmed} and Ibtihal Fadhil and Hamladji, {Rose Marie} and Hamidieh, {Amir Ali} and Omar Fahmy and Saloua Ladeb and Kamran Alimoghaddam and Alaa Elhaddad and Nacer, {Redhouane Ahmed} and Fahad Alsharif and Walid Rasheed and Mohammad Jahani and Mousavi, {Seyed Asadollah} and Amal Alseraihy and Fawzi Abdel-Rahman and {Al Jefri}, Abdullah and Hussein, {Ayad Ahmed} and Abdulaziz Alabdulaaly and Ahmad Ibrahim and Bekadja, {Mohamed Amine} and Miguel Abboud and Parvez Ahmed and David Dennison and Mohammad Bakr and Said Benchekroun and Fazal Hussain and Othman, {Tarek Ben} and Mahmoud Aljurf and Ardeshir Ghavamzadeh",
year = "2011",
doi = "10.5144/1658-3876.2011.81",
language = "English",
volume = "4",
pages = "81--93",
journal = "Hematology/ Oncology and Stem Cell Therapy",
issn = "1658-3876",
publisher = "King Faisal Specialist Hospital and Research Centre",
number = "2",

}

TY - JOUR

T1 - Hematopoietic Stem Cell Transplantation in the Eastern Mediterranean Region (EMRO) 2008-2009

T2 - Report on behalf of the Eastern Mediterranean Bone Marrow Transplantation (EMBMT) Group

AU - Mohamed, Said Yousef Ahmed

AU - Fadhil, Ibtihal

AU - Hamladji, Rose Marie

AU - Hamidieh, Amir Ali

AU - Fahmy, Omar

AU - Ladeb, Saloua

AU - Alimoghaddam, Kamran

AU - Elhaddad, Alaa

AU - Nacer, Redhouane Ahmed

AU - Alsharif, Fahad

AU - Rasheed, Walid

AU - Jahani, Mohammad

AU - Mousavi, Seyed Asadollah

AU - Alseraihy, Amal

AU - Abdel-Rahman, Fawzi

AU - Al Jefri, Abdullah

AU - Hussein, Ayad Ahmed

AU - Alabdulaaly, Abdulaziz

AU - Ibrahim, Ahmad

AU - Bekadja, Mohamed Amine

AU - Abboud, Miguel

AU - Ahmed, Parvez

AU - Dennison, David

AU - Bakr, Mohammad

AU - Benchekroun, Said

AU - Hussain, Fazal

AU - Othman, Tarek Ben

AU - Aljurf, Mahmoud

AU - Ghavamzadeh, Ardeshir

PY - 2011

Y1 - 2011

N2 - Background: The Eastern Mediterranean Bone Marrow Transplantation (EMBMT) Group has accumulated over 25 years of data and experience in hematopoietic stem cell transplantation (HSCT), most particularly in hem-moglobinopathies, severe aplastic anemia (SAA), and inherited metabolic and immune disorders, in addition to hematologic malignancies peculiar to the region and where recent updates in trends in activities are warranted. Objectives: To study trends in HSCT activities in the World Health Organization-Eastern Mediterranean (EM) region surveyed by EMBMT between 2008 and 2009. STUDY DESIGN: Retrospective analysis of the survey data, mainly of the cumulative number of transplants, types of transplants (autologous vs. allogeneic), types of conditioning as myeloablative (MAC) vs. reduced intensity conditioning (RIC) and trends in leukemias, hemog-globinopathies, SAA, inherited bone marrow failure syndromes amongst others. Results And Discussion: Fourteen teams from ten Eastern Mediterranean Region Organization (EMRO) countries reported their data (100% return rate) to the EMBMT for the years 2008-2009 with a total of 2608 first HSCT (1286 in 2008; 1322 in 2009). Allogeneic HSCT represented the majority (63%) in both years. The main indications for allogeneic HSCT were acute leukemias (732; 44%), bone marrow failure syndromes (331, 20%), hemoglobinopathies (255; 15%) and immune deficiencies (90; 5%). There was a progressive increase in the proportions of chronic myeloid leukemia (CML) cases transplanted beyond the first chronic phase (3; 7% of all CML cases in 2008 vs 13; 29% in 2009). The main indications for autologous transplants were plasma cell disorders (345; 36%) Hodgkin disease (256; 27%), non-Hodgkin lymphoma (207; 22%) and solid tumors (83; 9%). RIC continued to show a progressive increase over the years (7% in 2007, 11% in 2008 and 13% in 2009), yet remained relatively low compared to contemporary practices in Europe published by EBMT. The vast majori-ity (95%) of allo-HSCT sources were from sibling donors with a continued dominance of peripheral blood (PB) (1076; 63%), while cord blood transplant (CBT) increased to 83 (5% of allo-HSCT), matched unrelated donor (MUD) remained underutilized (1; 0%) and there were no haploidentical transplants reported. Large centers with >50 HSCT/year showed a plateau of the total number of allo-HSCT over the last 5 years that may be related to capacity issues and needs further study. Conclusions And Recommendations: There is an overall increased rate of HSCT in the EMRO region with a significant increase in utilization of CBT and allogeneic PB-HSCT as a valuable source. However, further research on outcome data and development of regional donor banks (CB and MUD) may help facilitate future planning to satisfy the regional needs and increase collaboration within the group and globally.

AB - Background: The Eastern Mediterranean Bone Marrow Transplantation (EMBMT) Group has accumulated over 25 years of data and experience in hematopoietic stem cell transplantation (HSCT), most particularly in hem-moglobinopathies, severe aplastic anemia (SAA), and inherited metabolic and immune disorders, in addition to hematologic malignancies peculiar to the region and where recent updates in trends in activities are warranted. Objectives: To study trends in HSCT activities in the World Health Organization-Eastern Mediterranean (EM) region surveyed by EMBMT between 2008 and 2009. STUDY DESIGN: Retrospective analysis of the survey data, mainly of the cumulative number of transplants, types of transplants (autologous vs. allogeneic), types of conditioning as myeloablative (MAC) vs. reduced intensity conditioning (RIC) and trends in leukemias, hemog-globinopathies, SAA, inherited bone marrow failure syndromes amongst others. Results And Discussion: Fourteen teams from ten Eastern Mediterranean Region Organization (EMRO) countries reported their data (100% return rate) to the EMBMT for the years 2008-2009 with a total of 2608 first HSCT (1286 in 2008; 1322 in 2009). Allogeneic HSCT represented the majority (63%) in both years. The main indications for allogeneic HSCT were acute leukemias (732; 44%), bone marrow failure syndromes (331, 20%), hemoglobinopathies (255; 15%) and immune deficiencies (90; 5%). There was a progressive increase in the proportions of chronic myeloid leukemia (CML) cases transplanted beyond the first chronic phase (3; 7% of all CML cases in 2008 vs 13; 29% in 2009). The main indications for autologous transplants were plasma cell disorders (345; 36%) Hodgkin disease (256; 27%), non-Hodgkin lymphoma (207; 22%) and solid tumors (83; 9%). RIC continued to show a progressive increase over the years (7% in 2007, 11% in 2008 and 13% in 2009), yet remained relatively low compared to contemporary practices in Europe published by EBMT. The vast majori-ity (95%) of allo-HSCT sources were from sibling donors with a continued dominance of peripheral blood (PB) (1076; 63%), while cord blood transplant (CBT) increased to 83 (5% of allo-HSCT), matched unrelated donor (MUD) remained underutilized (1; 0%) and there were no haploidentical transplants reported. Large centers with >50 HSCT/year showed a plateau of the total number of allo-HSCT over the last 5 years that may be related to capacity issues and needs further study. Conclusions And Recommendations: There is an overall increased rate of HSCT in the EMRO region with a significant increase in utilization of CBT and allogeneic PB-HSCT as a valuable source. However, further research on outcome data and development of regional donor banks (CB and MUD) may help facilitate future planning to satisfy the regional needs and increase collaboration within the group and globally.

UR - http://www.scopus.com/inward/record.url?scp=79961005585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961005585&partnerID=8YFLogxK

U2 - 10.5144/1658-3876.2011.81

DO - 10.5144/1658-3876.2011.81

M3 - Article

C2 - 21727769

AN - SCOPUS:79961005585

VL - 4

SP - 81

EP - 93

JO - Hematology/ Oncology and Stem Cell Therapy

JF - Hematology/ Oncology and Stem Cell Therapy

SN - 1658-3876

IS - 2

ER -